News | September 6, 2017

Greenwood Genetic Center Partners With FDNA To Help Find Answers For Thousands Of Undiagnosed Rare Disease Patients


Today, Greenwood Genetic Center ( announces its partnership with FDNA ( The collaboration will use FDNA’s facial analysis and artificial intelligence technology to evaluate Greenwood Genetic Center’s (GGC) patient data in a de-identified way, aiding in new discoveries of genetically based rare diseases and helping to find long-awaited answers for those undiagnosed.

The collaboration involves the analysis of nearly 80,000 cases from GGC to further FDNA’s database strength on known diagnoses and gain insight into potential answers for patients without a diagnosis. GGC plans to analyze thousands of undiagnosed cases using FDNA’s next generation phenotyping technology: Face2Gene. The analysis of these cases is expected to produce actionable insights for undiagnosed patients, recognition of new syndrome-related clinical phenotypes, and achieve numerous other rare disease discoveries that will advance research globally. These results will help clinicians find answers for patients who have yet to find a diagnosis, most of whom are children exhibiting rare disease symptoms.

“The GGC clinical team has already received the first insights from FDNA,” said Hannah Warren, MS, CGC, Clinical Genetic Counselor at Greenwood Genetic Center. “There are dozens of high priority, undiagnosed cases that have been flagged by Face2Gene due to their statistically significant facial analysis insights. These new insights may help find a diagnosis for patients who have been searching for answers for much too long.”

Artificial Intelligence and Human Insight Combine to Find Answers for Undiagnosed Patients

The GGC-FDNA collaboration is critical to the future of rare disease research. One in 10 people worldwide suffers from a rare genetic disease. In the US alone there are 30 million people suffering from rare diseases—more than double the number of patients living with a cancer diagnosis. In addition to providing GGC with insights on undiagnosed cases, FDNA also uses the analysis of patient data in Face2Gene to highlight likely genetic variations in the patient’s genetics for the doctor to consider as they search for the answer among thousands of possibilities.

“Because of the complexity of the human genome and the sheer number of rare syndromes, geneticists have been, up to now, at an extreme disadvantage in coming to a diagnosis,” said Dekel Gelbman, CEO of FDNA. “Combining AI with big data is giving medical professionals the help they need to provide hope to these patients.”

Founded in 2011, FDNA is committed to helping clinicians, labs and researchers diagnose, treat and create therapies for rare diseases. FDNA’s Face2Gene suite of applications helps to quickly evaluate patients’ clinical signs through artificial intelligence and facial analysis. With a comprehensive database of more than 10,000 rare disease syndromes, this technology is supporting healthcare providers to improve the speed and accuracy of a diagnosis for rare disease patients.

About Greenwood Genetic Center
The Greenwood Genetic Center (GGC), founded in 1974, is a nonprofit organization advancing the field of medical genetics and caring for families impacted by genetic disease and birth defects. At its home campus in Greenwood, South Carolina, a talented team of physicians and scientists provides clinical genetic services, diagnostic laboratory testing, educational programs and resources, and research in the field of medical genetics. GGC’s faculty and staff are committed to the goal of developing preventive and curative therapies for the individuals and families they serve. GGC extends its reach as a resource to all residents of South Carolina with satellite offices in Charleston, Columbia, Florence and Greenville. For more information about GGC or the GGC Foundation, please visit

About FDNA and Face2Gene
FDNA is the developer of Face2Gene, a clinical suite of phenotyping applications that facilitates comprehensive and precise genetic evaluations. Face2Gene uses facial analysis, deep learning and artificial intelligence to transform big data into actionable genomic insights to improve and accelerate diagnostics and therapeutics. With the world’s largest network of clinicians, labs and researchers creating one of the fastest growing and most comprehensive genomic databases, FDNA is changing the lives of rare disease patients. For more information, visit

Copyright Business Wire 2017